Immunis, a clinical-stage biotech company, has launched non-terminal safety studies for canine muscle atrophy in partnership with VetBio Partners. This STEM-K9 program builds upon preclinical success observed in aged mouse models using Immunis’ investigational secretome (IMM01-STEM) and complements ongoing human clinical trials for STEM-MYO and STEM-META programs. The company aims to improve mobility and quality of life for canines, paralleling their human-focused research.
VetBio Partners, led by Dr. Peter Canning, brings over three decades of veterinary pharmaceutical experience to the collaboration. Dr. Canning’s expertise will be instrumental in guiding Immunis through the preclinical trials. The increasing importance of pets within families has driven demand for improved animal healthcare, particularly for age-related conditions.
Canine muscle atrophy, similar to its human counterpart, arises from aging, inactivity, and underlying health issues. Despite a clear link between age and decreased muscle mass in dogs, research in this area remains limited. Muscle loss also contributes to serious conditions like congestive heart failure, chronic kidney disease, cancer, and osteoarthritis in canines.
Immunis emphasizes that the animal studies adhere to the same rigorous standards employed in their human clinical trials. The non-terminal design of the study prioritizes the ethical treatment of the canine participants. This expansion into animal health demonstrates Immunis’ commitment to applying their innovative therapies across species, aiming to address age-related ailments in both humans and companion animals.
VetBio Partners offers research and development consulting services, specializing in bridging human health biopharmaceutical technologies to animal health applications. Their extensive network and experience in drug discovery and development facilitate the efficient evaluation of new technologies for efficacy and safety. They also provide business development support through connections within the animal health pharmaceutical industry.
Immunis focuses on developing an immunomodulatory secretome product targeting age and disease-related immune decline. Their investigational product utilizes secretome technology to deliver a natural, human-derived blend of immune modulators in physiologically relevant concentrations.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
